Department of Medicine, Division of Cardiology, Stanford University School of Medicine, 300 Pasteur Drive, Grant S140B, Stanford, CA 94305-5111, USA.
J R Soc Interface. 2010 Dec 6;7 Suppl 6(Suppl 6):S753-63. doi: 10.1098/rsif.2010.0353.focus. Epub 2010 Sep 29.
Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) have the ability (i) to duplicate indefinitely while maintaining pluripotency and (ii) to differentiate into cell types of all three embryonic germ layers. These two properties of ESCs and iPSCs make them potentially suitable for tissue engineering and cell replacement therapy for many different diseases, including Parkinson's disease, diabetes and heart disease. However, one critical obstacle in the clinical application of ESCs or iPSCs is the risk of teratoma formation. The emerging field of molecular imaging is allowing researchers to track transplanted ESCs or iPSCs in vivo, enabling early detection of teratomas.
胚胎干细胞（ESCs）和诱导多能干细胞（iPSCs）具有以下两个特性：（i）在保持多能性的同时无限复制，以及（ii）分化为所有三个胚胎胚层的细胞类型。这两个特性使得 ESCs 和 iPSCs 有可能适用于多种不同疾病的组织工程和细胞替代治疗，包括帕金森病、糖尿病和心脏病。然而，在 ESCs 或 iPSCs 的临床应用中，一个关键障碍是畸胎瘤形成的风险。分子成像这一新兴领域使研究人员能够在体内追踪移植的 ESCs 或 iPSCs，从而能够早期发现畸胎瘤。
